Risk of cervical cancer associated with extending the interval between cervical-cancer screenings
- PMID: 14561792
- DOI: 10.1056/NEJMoa035419
Risk of cervical cancer associated with extending the interval between cervical-cancer screenings
Abstract
Background: Although contemporary guidelines suggest that the intervals between Papanicolaou tests can be extended to three years among low-risk women with previous negative tests, the excess risk of cervical cancer associated with less frequent than annual screening is uncertain.
Methods: We determined the prevalence of biopsy-proven cervical neoplasia among 938,576 women younger than 65 years of age, stratified according to the number of previous consecutive negative Papanicolaou tests. Using a Markov model that estimates the rate at which dysplasia will progress to cancer, we estimated the risk of cancer within three years after one or more negative Papanicolaou tests, as well as the number of additional Papanicolaou tests and colposcopic examinations that would be required to avert one case of cancer given a particular interval between screenings.
Results: Among 31,728 women 30 to 64 years of age who had had three or more consecutive negative tests, the prevalence of biopsy-proven cervical intraepithelial neoplasia of grade 2 was 0.028 percent and the prevalence of grade 3 neoplasia was 0.019 percent; none of the women had invasive cervical cancer. According to our model, the estimated risk of cancer with annual Papanicolaou tests for three years was 2 in 100,000 among women 30 to 44 years of age, 1 in 100,000 among women 45 to 59 years of age, and 1 in 100,000 among women 60 to 64 years of age; these risks would be 5 in 100,000, 2 in 100,000, and 1 in 100,000, respectively, if screening were performed once three years after the last negative test. To avert one additional case of cancer by screening 100,000 women annually for three years rather than once three years after the last negative test, an average of 69,665 additional Papanicolaou tests and 3861 colposcopic examinations would be needed in women 30 to 44 years of age and an average of 209,324 additional Papanicolaou tests and 11,502 colposcopic examinations in women 45 to 59 years of age.
Conclusions: As compared with annual screening for three years, screening performed once three years after the last negative test in women 30 to 64 years of age who have had three or more consecutive negative Papanicolaou tests is associated with an average excess risk of cervical cancer of approximately 3 in 100,000.
Copyright 2003 Massachusetts Medical Society
Comment in
-
How often should we screen for cervical cancer?N Engl J Med. 2003 Oct 16;349(16):1495-6. doi: 10.1056/NEJMp038147. N Engl J Med. 2003. PMID: 14561789 No abstract available.
-
Extending the interval between cervical-cancer screenings.N Engl J Med. 2004 Jan 22;350(4):414-5; author reply 414-5. doi: 10.1056/NEJM200401223500419. N Engl J Med. 2004. PMID: 14736937 No abstract available.
Similar articles
-
Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.J Obstet Gynaecol. 2020 Feb;40(2):240-246. doi: 10.1080/01443615.2019.1621813. Epub 2019 Jul 25. J Obstet Gynaecol. 2020. PMID: 31340702
-
Human papillomavirus and Papanicolaou tests to screen for cervical cancer.N Engl J Med. 2007 Oct 18;357(16):1589-97. doi: 10.1056/NEJMoa073204. N Engl J Med. 2007. PMID: 17942872 Clinical Trial.
-
Factors associated with an increased risk of prevalent and incident grade III cervical intraepithelial neoplasia and invasive cervical cancer among women with Papanicolaou tests classified as grades I or II cervical intraepithelial neoplasia.Am J Obstet Gynecol. 2002 Jan;186(1):28-34. doi: 10.1067/mob.2002.118918. Am J Obstet Gynecol. 2002. PMID: 11810080
-
Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force.Ann Intern Med. 2011 Nov 15;155(10):698-705, W216. doi: 10.7326/0003-4819-155-10-201111150-00377. Epub 2011 Oct 17. Ann Intern Med. 2011. PMID: 22006929 Review.
-
Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management.Obstet Gynecol Surv. 2006 Jun;61(6 Suppl 1):S15-25. doi: 10.1097/01.ogx.0000221011.01750.25. Obstet Gynecol Surv. 2006. PMID: 16729900 Review.
Cited by
-
Evaluation of Human Papillomavirus Vaccination and Cancer Prevention Behaviors among LGBTQI + Individuals: A Cross-Sectional Study.J Community Health. 2024 Sep 5. doi: 10.1007/s10900-024-01401-1. Online ahead of print. J Community Health. 2024. PMID: 39235543
-
Cervical Cancer Screening Recommendations: Now and for the Future.Healthcare (Basel). 2023 Aug 11;11(16):2273. doi: 10.3390/healthcare11162273. Healthcare (Basel). 2023. PMID: 37628471 Free PMC article. Review.
-
Papillomaviruses and cancer: commonalities and differences in HPV carcinogenesis at different sites of the body.Int J Clin Oncol. 2023 Aug;28(8):956-964. doi: 10.1007/s10147-023-02340-y. Epub 2023 May 18. Int J Clin Oncol. 2023. PMID: 37199886 Free PMC article. Review.
-
Mapping Evidence on Management of Cervical Cancer in Sub-Saharan Africa: Scoping Review.Int J Environ Res Public Health. 2022 Jul 28;19(15):9207. doi: 10.3390/ijerph19159207. Int J Environ Res Public Health. 2022. PMID: 35954564 Free PMC article. Review.
-
Interventions targeted at women to encourage the uptake of cervical screening.Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3. Cochrane Database Syst Rev. 2021. PMID: 34694000 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials